Investors bought shares of Eli Lilly and Company (NYSE:LLY) on weakness during trading on Monday following insider selling activity. $56.08 million flowed into the stock on the tick-up and $28.40 million flowed out of the stock on the tick-down, for a money net flow of $27.68 million into the stock. Of all companies tracked, Eli Lilly and had the 18th highest net in-flow for the day. Eli Lilly and traded down ($0.43) for the day and closed at $82.86Specifically, SVP Alfonso G. Zulueta sold 2,003 shares of Eli Lilly and stock in a transaction on Friday, November 10th. The stock was sold at an average price of $83.67, for a total transaction of $167,591.01. Following the completion of the transaction, the senior vice president now directly owns 43,580 shares of the company’s stock, valued at $3,646,338.60. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, major shareholder Lilly Endowment Inc sold 190,000 shares of Eli Lilly and stock in a transaction on Friday, September 15th. The stock was sold at an average price of $82.53, for a total value of $15,680,700.00. Following the transaction, the insider now directly owns 123,682,287 shares of the company’s stock, valued at $10,207,499,146.11. The disclosure for this sale can be found here. Insiders sold a total of 772,003 shares of company stock valued at $64,837,441 over the last three months. Insiders own 0.20% of the company’s stock.
Several equities analysts recently issued reports on the company. BMO Capital Markets set a $73.00 price objective on Eli Lilly and and gave the stock a “sell” rating in a report on Tuesday, October 24th. Barclays PLC lifted their price objective on Eli Lilly and from $90.00 to $98.00 and gave the stock an “overweight” rating in a report on Friday, October 13th. Berenberg Bank reaffirmed a “buy” rating and set a $98.00 price objective on shares of Eli Lilly and in a report on Thursday, October 26th. Zacks Investment Research downgraded Eli Lilly and from a “buy” rating to a “hold” rating in a research report on Monday, October 30th. Finally, Cowen and Company reissued a “buy” rating and set a $95.00 price target on shares of Eli Lilly and in a research report on Wednesday, October 4th. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $89.76.
The company has a market capitalization of $91,710.21, a price-to-earnings ratio of 20.36, a price-to-earnings-growth ratio of 1.83 and a beta of 0.34. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.03 and a current ratio of 1.38.
Eli Lilly and (NYSE:LLY) last issued its quarterly earnings data on Tuesday, October 24th. The company reported $1.05 EPS for the quarter, topping the Zacks’ consensus estimate of $1.03 by $0.02. The company had revenue of $5.66 billion for the quarter, compared to analysts’ expectations of $5.52 billion. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. The firm’s quarterly revenue was up 9.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.88 earnings per share. research analysts forecast that Eli Lilly and Company will post 4.22 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 8th. Shareholders of record on Wednesday, November 15th will be paid a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.51%. The ex-dividend date of this dividend is Tuesday, November 14th. Eli Lilly and’s dividend payout ratio is presently 98.58%.
Several institutional investors and hedge funds have recently modified their holdings of the business. Nomura Asset Management Co. Ltd. lifted its stake in shares of Eli Lilly and by 10.5% during the third quarter. Nomura Asset Management Co. Ltd. now owns 611,105 shares of the company’s stock worth $52,274,000 after purchasing an additional 58,011 shares in the last quarter. Caisse DE Depot ET Placement DU Quebec lifted its stake in shares of Eli Lilly and by 2.0% during the third quarter. Caisse DE Depot ET Placement DU Quebec now owns 394,200 shares of the company’s stock worth $33,862,000 after purchasing an additional 7,800 shares in the last quarter. Brave Asset Management Inc. lifted its stake in shares of Eli Lilly and by 9.9% during the third quarter. Brave Asset Management Inc. now owns 10,929 shares of the company’s stock worth $935,000 after purchasing an additional 985 shares in the last quarter. Synovus Financial Corp lifted its stake in shares of Eli Lilly and by 0.8% during the third quarter. Synovus Financial Corp now owns 196,642 shares of the company’s stock worth $16,848,000 after purchasing an additional 1,537 shares in the last quarter. Finally, Envestnet Asset Management Inc. lifted its stake in shares of Eli Lilly and by 0.5% during the third quarter. Envestnet Asset Management Inc. now owns 217,695 shares of the company’s stock worth $18,626,000 after purchasing an additional 1,003 shares in the last quarter. Institutional investors own 75.48% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This news story was published by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are accessing this news story on another domain, it was stolen and reposted in violation of United States & international trademark and copyright law. The original version of this news story can be viewed at https://www.truebluetribune.com/2017/11/14/investors-buy-eli-lilly-and-company-lly-on-weakness-after-insider-selling.html.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.